
Wednesday, September 05, 2018 9:50:11 PM
P2.09-24 - MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
16:45 - 18:00 | Presenting Author(s): Rebecca Mosher | Author(s): Hui Yu, Kim Ellison, Pamela Shaw, Rafal Dziadziuszko, Eric Hailman, Christopher J. Rivard, Fred R. Hirsch
Abstract
Background
NaPi2b is a sodium-dependent phosphate transporter expressed in lung, ovarian, and thyroid cancers. Prior studies have suggested an enrichment of expression in lung adenocarcinoma (ACA).
XMT-1536 is a NaPi2b targeting ADC (Antibody Drug Conjugate) comprised of a humanized antibody (XMT-1535) conjugated with 10-15 auristatin F-HPA (AF-HPA) payload molecules via the Dolaflexin platform. AF-HPA is capable of controlled bystander-effect killing, resulting in efficacy in models with heterogeneous antigen expression, and is metabolized intra-tumorally to an active non-permeable metabolite to enable greater systemic tolerability. Previously, we demonstrated pre-clinical activity of XMT-1536 in human primary xenograft models of non-small cell lung cancer (NSCLC).
MERS67 is a human-rabbit chimeric antibody derived from XMT-1535. MERS67 has been formatted for use as an immunohistochemical reagent by multiple methods and expression has been shown to correlate with response in an unselected series of primary ovarian cancer xenografts. (AACR-EORTC, 2017)
We evaluated MERS67 to see if it would preferentially stain lung adenocarcinoma (ACA), as has been demonstrated using other NaPi2b antibodies.
Method
An immunohistochemical assay for MERS67 was established on a Leica BondRx Instrument. The assay was performed on tissue microarrays (TMA), including NSCLC and small cell lung cancer (SCLC) cell line arrays, and a NSCLC human tumor array. Tumors in the NSCLC array had previously been classified based on morphologic features only. All arrays were scored based on the H-score method.
To characterize the primary tumors further, the tumor TMA was stained with TTF-1 and p40, markers of ACA and squamous cell carcinoma (SqCC), respectively. Results of this staining were compared to MERS67 staining patterns.
Result
H-Scores in the NSCLC cell line TMA ranged from 0-260, and from 0-100 in the SCLC TMA. Within the tissue microarray, 99 individual cases were evaluable. By morphologic classification 63 cases were SqCC, and 23 cases were ACA. Using an arbitrary cut point of H=50, there was a statistically significant difference in the number of NaPi2b positive ACA cases (19/23) vs SqCC (3/63). Among 43 cases where p40 and TTF-1 were evaluable and were in agreement with morphologic diagnosis, 7/7 cases of ACA were positive for NaPi2b, while 0/36 SqCC were positive.
Conclusion
MERS67 is an anti-NaPi2b antibody that frequently demonstrates immunoreactivity in lung ACA. MERS67 is a chimeric antibody related to XMT-1536, a proprietary anti-NaPi2b ADC. Target expression using MERS67 is being evaluated in an ongoing XMT-1536 Phase 1 clinical trial enrolling non-squamous NSCLC patients.

Liked By
Spread the love. Be the first to like this post!
Recent MRSN News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/03/2023 09:05:00 PM
- Mersana Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/02/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/01/2023 01:19:18 PM
- Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer • GlobeNewswire Inc. • 02/01/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/31/2023 07:02:46 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/25/2023 01:25:17 PM
- Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors • GlobeNewswire Inc. • 01/25/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/19/2023 09:07:23 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/06/2023 09:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 12:19:46 PM
- Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones • GlobeNewswire Inc. • 01/06/2023 12:00:18 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/27/2022 12:03:21 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/22/2022 09:23:22 PM
- Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates • GlobeNewswire Inc. • 12/22/2022 09:05:10 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 09:47:13 PM
- European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 12/14/2022 01:00:00 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/02/2022 09:05:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/02/2022 09:03:03 PM
- SVB Securities Sticks to Their Buy Rating for Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:27:37 AM
- Robert W. Baird Remains a Buy on Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:16:29 AM
- Mersana Therapeutics to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 09:06:49 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 11/07/2022 09:03:59 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/07/2022 01:49:36 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 12:11:32 PM
TNRG Signs Reg A Offering Agreement • TNRG • Feb 3, 2023 10:30 AM
Trend Innovations Holding Inc. Thy News Application Review Year 2022 and Update Toward 2023 • TREN • Feb 2, 2023 2:00 PM
Goldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone Widths of Mineralized System Expanded Significantly. • GSHRF • Feb 2, 2023 9:58 AM
Hempacco and Snoop Dogg Create Joint Venture to Launch Consumer Goods Powerhouse of Hemp and Hemp-Derived Products • HPCO • Feb 2, 2023 9:30 AM
Kona Gold Beverage, Inc Announces Record Revenue Month in January Eclipsing Half a Million Dollars for the First Time • KGKG • Feb 2, 2023 9:00 AM
BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm • BLFE • Feb 2, 2023 8:32 AM